CA3235574A1 — Salt forms of a complement component c5a receptor
Assigned to Chemocentryx Inc · Expires 2021-05-14 · 5y expired
What this patent protects
A tosylate salt of Compound 1, and use of the salt for treatment of an individual suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors. The salt is characterized by an X-ray powder diffraction pattern comprising peaks at 7.6, 10.…
USPTO Abstract
A tosylate salt of Compound 1, and use of the salt for treatment of an individual suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors. The salt is characterized by an X-ray powder diffraction pattern comprising peaks at 7.6, 10.8, 13.1, 16.5, 19.7, 21.6 degrees 20 ( 0.2 degrees 20).
Drugs covered by this patent
- Tavneos (AVACOPAN) · Chemocentryx
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.